Olsen E A, Bunn P A
Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Hematol Oncol Clin North Am. 1995 Oct;9(5):1089-107.
All of the recombinant interferons are active agents for the systemic treatment of mycosis fungoides and Sézary syndrome. The response rates are similar to those observed with systemic chemotherapy. There is no clear evidence that combining interferons with other systemic therapies increases the response rates. The combination of interferon with PUVA provides provocative results. The optimal role of interferons in the treatment of mycosis fungoides and Sézary's syndrome is undefined.
所有重组干扰素都是蕈样肉芽肿和塞扎里综合征全身治疗的活性药物。其缓解率与全身化疗的缓解率相似。没有明确证据表明将干扰素与其他全身治疗联合使用能提高缓解率。干扰素与补骨脂素紫外线A光化学疗法（PUVA）联合使用产生了令人鼓舞的结果。干扰素在蕈样肉芽肿和塞扎里综合征治疗中的最佳作用尚不清楚。
